LitAlert ~~ GeneLit.com

    • Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance.
    • Overbeek KA, Cahen DL, Kamps A, Konings ICAW, Harinck F, Kuenen MA, Koerkamp BG, Besselink MG, van Eijck CH, Wagner A, Ausems MGE, van der Vlugt M, Fockens P, Vleggaar FP, Poley JW, van Hooft JE, Bleiker EMA, Bruno MJ, the Dutch Familial Pancreatic Cancer Surveillance Study Group.
    • Fam Cancer. 2020 Mar 19. doi: 10.1007/s10689-020-00171-8. [Epub ahead of print]

    • Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test.
    • Hamilton JG, Genoff Garzon M, Shah IH, Cadet K, Shuk E, Westerman JS, Hay JL, Offit K, Robson ME
    • Public Health Genomics. 2020 Mar 19. doi: 10.1159/000505854. [Epub ahead of print]

    • Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    • Rush SK, Swisher EM, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM.
    • Gynecol Oncol. 2020 Mar 18. pii: S0090-8258(20)30101-3. doi: 10.1016/j.ygyno.2020.02.006. [Epub ahead of print]

    • Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
    • Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2020 Mar 17;13(1):29. doi: 10.1186/s13048-020-00629-4.

    • Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?
    • Shanmugan S, Sammel MD, Loughead J, Ruparel K, Gur RC, Brown TE, Faust J, Domchek S, Epperson CN.
    • Menopause. 2020 Mar 16. doi: 10.1097/GME.0000000000001535. [Epub ahead of print]

    • ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
    • Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP.
    • Cancers (Basel). 2020 Mar 14;12(3). pii: E687. doi: 10.3390/cancers12030687.

    • Therapeutic options for mucinous ovarian carcinoma.
    • Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.
    • Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2.

    • [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
    • Marom I, Lavie O, Ostrovsky L, Kugelman N, Schmidt M, Segev Y.
    • Harefuah. 2020 Mar;159(3):175-180.
    • Review, [Article in Hebrew]

    • Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.
    • Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y.
    • Front Oncol. 2020 Feb 28;10:301. doi: 10.3389/fonc.2020.00301. eCollection 2020.